Table 4.
Evaluation results of the clinical samples.
| Date | Number | Number of Positive Samples | |||||
|---|---|---|---|---|---|---|---|
| PEDV (%) | TGEV (%) | PDCoV (%) | SADS-CoV (%) | PEDV + TGEV (%) | PEDV + PDCoV (%) | ||
| October, 2020 | 200 | 26 (13.00%) | 3 (1.50%) | 30 (15.00%) | 0 | 0 | 15 (7.50%) |
| March, 2021 | 112 | 32 (28.57%) | 1 (0.89%) | 71 (63.39%) | 0 | 1 (0.89%) | 12 (10.71%) |
| October, 2021 | 37 | 6 (16.22%) | 0 | 0 | 0 | 0 | 0 |
| November, 2021 | 217 | 3 (1.38%) | 0 | 1 (0.46%) | 0 | 0 | 0 |
| January, 2022 | 314 | 90 (28.66%) | 0 | 64 (20.38%) | 0 | 0 | 4 (1.27%) |
| February, 2022 | 394 | 110 (27.92%) | 0 | 74 (18.78%) | 0 | 0 | 1 (0.25%) |
| March, 2022 | 244 | 16 (6.56%) | 0 | 40 (16.39%) | 0 | 0 | 0 |
| April, 2022 | 378 | 95 (25.13%) | 1 (0.26%) | 26 (6.88%) | 0 | 0 | 2 (0.53%) |
| May, 2022 | 30 | 4 (13.33%) | 0 | 0 | 0 | 0 | 0 |
| June, 2022 | 496 | 58 (11.69%) | 0 | 2 (0.40%) | 0 | 0 | 0 |
| July, 2022 | 287 | 47 (16.38%) | 0 | 33 (11.50%) | 0 | 0 | 4 (1.39%) |
| August, 2022 | 76 | 14 (18.42%) | 2 (2.63%) | 11 (14.47%) | 0 | 0 | 0 |
| September, 2022 | 92 | 23 (25.00%) | 2 (2.17%) | 16 (17.39%) | 1 (1.09%) | 0 | 2 (2.17%) |
| October, 2022 | 359 | 67 (18.66%) | 6 (1.67%) | 58 (16.16%) | 4 (1.11%) | 1 (0.28%) | 6 (1.67%) |
| Total | 3236 | 591 (18.26%) | 15 (0.46%) | 426 (13.16%) | 5 (0.15%) | 2 (0.06%) | 46 (1.42%) |